Glutathione synthesis system (GSH synthesis)

The glutathione synthesis system is a two-step enzymatic pathway responsible for producing glutathione (GSH), the most abundant non-protein thiol and a master antioxidant in eukaryotic cells (PubChem, 2024). The process is catalyzed by glutamate-cysteine ligase (GCL), the rate-limiting enzyme, followed by glutathione synthetase (GSS) (UniProt, 2024). GSH plays a critical role in maintaining cellular redox homeostasis, detoxifying xenobiotics, and protecting cells from oxidative damage caused by reactive oxygen species (PubMed, PMID: 24491681). In oncology, the system is often targeted for inhibition because many cancer cells overexpress GSH to survive high levels of oxidative stress and resist chemotherapy (PubMed, PMID: 28231310). Conversely, in neurodegenerative and inflammatory diseases, therapeutic strategies aim to upregulate the system to restore antioxidant capacity (StatPearls, 2023). Drugs like buthionine sulfoximine (BSO) act by inhibiting GCL, while N-acetylcysteine (NAC) serves as a precursor to boost synthesis (NIH, 2024). The system also interacts with the cystine/glutamate antiporter (System Xc-), which provides the rate-limiting amino acid cysteine (PubMed, PMID: 22460903). Modulation of this system is a key strategy in treating conditions ranging from acetaminophen overdose to advanced malignancies.

Other names

Glutathione biosynthetic pathwayGSH metabolismGamma-glutamyl cycleGSH synthesis pathway

Pharmacological modulation involves either the competitive inhibition of glutamate-cysteine ligase (GCL) to deplete cellular GSH pools, primarily used to sensitize tumor cells to oxidative stress, or the provision of rate-limiting substrates like L-cysteine (via NAC) to enhance GSH production in states of oxidative depletion (PubMed, PMID: 24491681). Additionally, indirect modulation occurs through the induction of Nrf2-mediated gene expression of GCL subunits or the inhibition of upstream amino acid transporters like System Xc- (PubMed, PMID: 22460903).